PSORIASIS

Marta Ferrán
Servicio de Dermatología
Hospital del Mar. Barcelona
PS1. GENETICS AND IMMUNOPATHOGENESIS OF PUSTULAR VARIANTS OF PSORIASIS (H. Bachelez)

- Genetically-inherited IL-36RA structural and functional abnormalities play a major role in GPP
- IL-36RN severely impairing mutations are preferentially associated with the most severe phenotypes
- IL36RN mutations are associated with an earlier age of onset across all variants of pustular psoriasis
• **CARD14** mutations are observed in only a small minority of cases
  • CARD-14 mutations in GPP, PPP and PRP impact on NFkB and IL-36 pathways

• **AP1S3** mutations occur with comparable frequency across disease types
  • AP1S3 mutations are associated with impaired Toll-like Receptor 3 trafficking

• Respiratory virus triggering events are involved in GPP / DITRA flares

• Results from early phase development of IL-36RA-blocking strategies are promising in GPP

![Graph showing GPPFA Score of 0 or 1 over time](image)
FOCUS SESSION: ADVANCES IN TARGET-ORIENTED THERAPY. PSORIASIS (B. Kirby)

• Anti-IL-17A (secukinumab, ixekizumab, brodalumab)
  • Long-term efficacy data
  • Long-term safety data
  • Rapid onset of action

• Bimekizumab (anti-IL17A/F)

• Anti-p19 IL23 (guselkumab, risankizumab, tildrakizumab, mirikizumab)
  • Efficacy / safety data
  • Maintenance of PASI-90 response after withdrawal
FOCUS SESSION: ADVANCES IN TARGET-ORIENTED THERAPY. PSORIATIC ARTHRITIS (W. Boehncke)

• Anti-TNFs are still the gold standard therapy

• New therapies
  • Anti-IL-17A/F, IL-23p19
  • JAK inhibition

• Assessment might be improved through replacing ACR criteria by PSA-focused measures (MDA?)

• T2T is about to become a widely established therapeutic strategy
PO.18: ADALIMUMAB VS ADALIMUMAB + MTX IN PSORIASIS: FIRST-YEAR RESULTS ON EFFECTIVENESS, DRUG SURVIVAL, SAFETY AND IMMUNOGENECITY (G. Kraaij, Amsterdam)

- Pragmatic RCT, assessor blinded
- Adalimumab vs adalimumab (n=30) + MTX 10mg / week (n=31)
  - PASI ≥ 8 (eligible according to guidelines)
  - Adalimumab naive
  - Follow-up every 12w for 3 years: 1rt year results (week 49)
- PASI-75:
  - 31% ADA vs 58% ADA+MTX (p=0.04)
- ADA survival:
  - 59% ADA vs 74 % ADA + MTX (p=0.26)
- Antidrug antibodies:
  - 47% ADA vs 16% ADA + MTX (p=0.01)
GRACIAS